Unlike patients with advanced or recurrent NSCLC, whose personalized therapy is guided by a range of oncogenic driver mutations and PD-L1 levels, identifying biomarkers and therapeutic targets in SCLC continues to pose a challenge. Here, CD274 is linked to non-small cell lung carcinoma.